Amneal Pharmaceuticals vs Bausch + Lomb

Amneal Pharmaceuticals (AMRX), health care, and Bausch + Lomb (BLCO), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Amneal Pharmaceuticals and Bausch + Lomb are valued at about the same: $7.4B and $7.4B. Amneal Pharmaceuticals's operating margin in its latest fiscal year was 13.1% and Bausch + Lomb's 2.22%. Over the past year Amneal Pharmaceuticals's share price has moved +83.5% and Bausch + Lomb's +38.3%.

Key facts

Amneal Pharmaceuticals market value
$7.4B
Bausch + Lomb market value
$7.4B
Amneal Pharmaceuticals P/E
52.8
Amneal Pharmaceuticals revenue
$3BFY to 2025-12-31
Bausch + Lomb revenue
$5.1BFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Amneal Pharmaceuticals vs Bausch + Lomb: every measure side by side
Measure Amneal Pharmaceuticals Bausch + Lomb
SectorHealth CareHealth Care
Country United States Canada
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.4Blower$7.4Bhigher
Revenue$3Blower$5.1Bhigher
Earnings$72.1Mhigher-$360Mlower
Employees8,700lower13,000higher
Total assets$3.7Blower$14Bhigher
Valuation
P/E52.8—
P/S2.4higher1.5lower
P/B13.8—
Dividend yield0.00%—
Profitability
Operating margin13.1%higher2.22%lower
Balance sheet
Net assets-$70.8Mlower$6.4Bhigher
Total liabilities$3.7Blower$7.5Bhigher
Total debt$2.6Blower$5Bhigher
Cash on hand$282Mlower$383Mhigher
Price change
Today-0.52%lower-0.24%higher
1 year+83.5%higher+38.3%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Amneal Pharmaceuticals only (0)

None of the tracked investors.

Bausch + Lomb only (4)

Percentages are each holding's share of that investor's reported portfolio. · Who owns BLCO

Further comparisons

Learn

Questions and answers

Which is bigger, Amneal Pharmaceuticals or Bausch + Lomb?

By market value, Bausch + Lomb is the larger: $7.4B against $7.4B for Amneal Pharmaceuticals. By revenue in its latest fiscal year, Bausch + Lomb is the larger: $5.1B against $3B for Amneal Pharmaceuticals.

Which has the higher operating margin?

Amneal Pharmaceuticals: 13.1%, against 2.22% for Bausch + Lomb. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Bausch + Lomb: $5B, against $2.6B for Amneal Pharmaceuticals. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Amneal Pharmaceuticals and Bausch + Lomb?

None of the tracked superinvestors holds both in their latest 13F filing. 0 hold Amneal Pharmaceuticals and 4 hold Bausch + Lomb.

Cite this page

Funkfolio, “Amneal Pharmaceuticals vs Bausch + Lomb”, data as of 17 November 2026. https://funkfolio.com/compare/amrx-vs-blco

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.